Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients by Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Salazar, MA, Fitzsimons, E, Estevez, MO, Towfic, F, Flynt, E, Pierceall, WE, Yong, K, Vyas, P, Thakurta, A

Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma by Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Polonskaia, A, Angulo Salazar, M, Fitzsimons, E, Sirinukunwattana, K, Chavda, SJ, Ortiz Estevez, M, Towfic, F, Flynt, E, Pierceall, W, Royston, D, Yong, KL, Ramasamy, K, Vyas, P, Thakurta, A

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma by Kurata, K, James-Bott, A, Tye, MA, Yamamoto, L, Samur, MK, Tai, Y-T, Dunford, J, Johansson, C, Senbabaoglu, F, Philpott, M, Palmer, C, Ramasamy, K, Gooding, S, Smilova, M, Gaeta, G, Guo, M, Christianson, JC, Payne, NC, Singh, K, Karagoz, K, Stokes, ME, Ortiz, M, Hagner, P, Thakurta, A, Cribbs, A, Mazitschek, R, Hideshima, T, Anderson, KC, Oppermann, U